Abstract:It has previously been observed in animal studies that, at equivalent doses, radioimmunotherapy (RIT) is 2.5 times more effective than multiple fractions of external beam radiation therapy (EBRT) in inhibiting tumour growth. In this study, we compared the use of RIT and EBRT in patients with hepatocellular carcinoma (HCC), treated during the past 10 years. Of 67 patients without extrahepatic involvement, 32 were treated with hepatic artery ligation combined with RIT (the RIT group) while 35 were treated with a combination of hepatic arterial chemo-embolisation and EBRT (the EBRT group). The patients in the RIT group received 131I-Hepama-1 monoclonal antibody, which was infused through the hepatic artery catheter. The patients in the EBRT group received transcatheter arterial chemo-embolisation and limited-field EBRT using a linear accelerator. Parameters observed include tumour response, alpha-fetoprotein (AFP) level in serum, human anti-murine antibody (HAMA) assay, T lymphocyte subsets, survival rates, routine parameters, sequential resection rates and histopathological status of the resection specimens. The sequential resection rates were 53% (17/32) and 23% (8/35), and tumour response rates were 72% (23/32) and 86% (30/35) in the RIT and EBRT groups, respectively. The main side-effects in the RIT group were mild allergic reactions. The most common toxicity in the EBRT group was an increase in liver enzymes. The liver tissue in the target volume was injured by EBRT. The injured liver tissue revealed a low-attenuation area adjacent to the hepatic tumour within the target volume on follow-up computed tomography studies after EBRT. On pathological evaluation, the low-attenuation area revealed hyperaemia, distended hepatic sinusoids packed with erythrocytes and hepatic cell loss. The sequential resection specimens from both the RIT and the EBRT group showed residual cancer tissue located at the edge of the mass. The residual cancer cells presented as giant cells under microscopy. T lymphocyte subsets observed prior to treatment did not significantly change after RIT, but were significantly disturbed by EBRT. HAMA formation was the major reason for discontinuing RIT, the incidence being as high as 34% (11/32). Intrahepatic and pulmonary metastases occurred more frequently in the EBRT group (63%) than in the RIT group (22%). The 1-, 2-, 3- and 4-year survival rates were 50%, 41%, 34% and 31% in the RIT group, and 77%, 39%, 11% and 7% in the EBRT group, respectively. It is interesting that the serum AFP level showed a transient increase, the mechanism and importance of which are not known, but are discussed. Both RIT and EBRT are useful treatment modalities for unresectable HCC, serving to prolong survival. However, RIT is much less toxic than EBRT, the side-effects of which include radiation injury to the liver and disturbance of T lymphocyte subsets.

Improved Long-Term Survival for Unresectable Hepatocellular Carcinoma (HCC) with a Combination of Surgery and Intrahepatic Arterial Infusion of 131 I-anti-HCC Mab. Phase I/II Clinical Trials

INTRAHEPATIC ARTERIAL I-131 ANTI-HEPATOCELLULAR CARCINOMA (HCC) MONOCLONAL-ANTIBODY COMBINED WITH HEPATIC-ARTERY LIGATION FOR TREATMENT OF UNRESECTABLE HCC

Enhanced Efficacy of Direct Immunochemotherapy for Hepatic Cancer with Image-Guided Intratumoral Radiofrequency Hyperthermia

Radioiodinated Anti-Hepatocellular Carcinoma (HCC) Ferritin Targeting Therapy, Tumor Imaging and Anti-Antibody Response in HCC Patients with Hepatic Arterial Infusion

Radioimmunotherapy in Treatment of Unresectable Hepatoma—a Report of 43 Cases

Phase I Clinical Trial of Targeted Therapy Using 131I-Hepama-1 Mab in Patients with Hepatocellular Carcinoma

Systemic Chemotherapy Improves Outcome of Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

131 I-Labeled-Metuximab Plus Transarterial Chemoembolization in Combination Therapy for Unresectable Hepatocellular Carcinoma: Results from a Multicenter Phase IV Clinical Study.

Comparison Between Radioimmunotherapy and External Beam Radiation Therapy for Patients with Hepatocellular Carcinoma

Hepatic Arterial Infusion Chemotherapy is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update

Effectiveness of Combined 131I-chTNT and Radiofrequency Ablation Therapy in Treating Advanced Hepatocellular Carcinoma

Radioimmunotherapy in the Multimodality Treatment of Hepatocellular Carcinoma with Reference to Second-Look Resection.

Hepatic arterial iodine-131-labeled metuximab injection combined with chemoembolization for unresectable hepatocellular carcinoma: interim safety and survival data from 110 patients.

Hepatic Artery Ligation and Infusion Chemotherapy for Unresectable Primary Liver Cancer.

Hepatic Artery Injection of 131 I-labelled Metuximab Combined with Chemoembolization for Intermediate Hepatocellular Carcinoma: a Prospective Nonrandomized Study

Radioimmunotherapy for Hepatocellular Carcinoma (HCC) Using 131I-Anti HCC Isoferritin IgG: Preliminary Results of Experimental and Clinical Studies

Hepatic Artery Injection of <SUP>131</SUP>I-Metuximab Combined with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Prospective Nonrandomized, Multicenter Clinical Trial

Sequential Transcatheter Arterial Chemoembolization, Three-Dimensional Conformal Radiotherapy, and High-Intensity Focused Ultrasound Treatment for Unresectable Hepatocellular Carcinoma Patients

Human Anti-(Murine Ig) Antibody Responses in Patients with Hepatocellular Carcinoma Receiving Intrahepatic Arterial 131 I-labeled Hepama-1 Mab. Preliminary Results and Discussion

Triple Combination Therapy Comprising Angiogenesis Inhibitors, Anti-Pd-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma.

Multimodality treatment and two-stage resection for unresectable hepatocellular carcinoma--experimental and clinical studies]